Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections
0
, ... Abstract
Hepatocellular carcinoma (HCC) is categorized among the most common primary malignant liver cancer and a primary global cause of death from cancer. HCC tends to affect males 2-4 times more than females in many nations. The main factors that raise the incidence of HCC are chronic liver diseases, hepatotropic viruses like hepatitis B (HBV) and C (HCV), non-alcoholic fatty liver disease, exposure to toxins like aflatoxin, and non-alcoholic steatohepatitis (NASH). Among these, hepatitis B and C are the most prevalent causes of chronic hepatitis globally. Metformin, which is made from a naturally occurring compound called galegine, derived from the plant Galega officinalis (G. officinalis), has been found to exhibit antitumor effects in a wide range of malignancies, including HCC. In fact, compared to patients on sulphonylureas or insulin, studies have demonstrated that metformin treatment significantly lowers the risk of HCC in patients with chronic liver disease. This article will first describe the molecular mechanism of hepatitis B and C viruses in the development of HCC. Then, we will provide detailed explanations about metformin, followed by a discussion of the association between metformin and hepatocellular carcinoma caused by the viruses mentioned above.
Keywords
INTRODUCTION
Over 700,000 cases of hepatocellular carcinoma (HCC), a form of liver cancer, are reported each year, making it one of the main causes of cancer-related deaths globally. More than 80% of this global health problem occurs in developing countries[1]. HCC is more commonly diagnosed in males, with 2-4 times higher incidence rates than in females in many countries[2]. The primary factors that increase the incidence of HCC include chronic liver disorders, hepatotropic viruses such as hepatitis B (HBV) and C (HCV) viruses, non-alcoholic fatty liver disease, the use of/toxins such as aflatoxin, and non-alcoholic steatohepatitis (NASH) [Figure 1][3,4]. Hepatitis B and C are the primary causes of chronic hepatitis globally, among these factors. Chronic viral hepatitis can cause cirrhosis or HCC if treatment is not received[5].
Figure 1. Risk factors associated with HCC development.
The eight different genotypes of the circular, double-stranded DNA virus known as HBV (A to H)[6]. HCV, on the other hand, is a single-stranded RNA virus that is divided into six different genotypes and shows significant genetic variability (I to VI)[7]. HBV-HCV co-infection can raise the chance of developing HCC in cirrhosis patients[8]. The incidence of HCC can increase by 2.9 times when combined with alcohol[9]. Due to its strong ability to increase insulin sensitivity and safety, the oral drug metformin has been extensively utilized for nearly 60 years to treat metabolic syndrome and type 2 diabetes[10]. The medication functions by stimulating AMP-activated protein kinase (AMPK), which decreases hepatic gluconeogenesis and raises skeletal muscle uptake of glucose. A key indicator of the state of cellular energy, AMPK is activated in human fibroblasts and several forms of cancer[11]. Intriguingly, recent reports have shown that metformin exhibits antitumor effects in many different cancers, such as HCC[12]. In actuality, patients with chronic liver disease who take metformin instead of sulphonylureas or insulin have a lower chance of developing HCC[13]. Metformin may have a direct effect on tumor-initiating HCC cells. In a study, rats were injected with celastrol, celastrol plus metformin for the treatment of HCC, and the potential of apoptosis was enhanced. The levels of caspase-9 and caspase-3 and Bax/BCL-2 were also observed. Metformin and celastrol suppressed NFκB, p65, TNFR, and TLR4 gene expression, preventing the activation caused by the phosphorylation of IκBκB and NFκBp65 and reducing the degradation of IκBα. Furthermore, the combined treatment of metformin plus celastrol suppressed angiogenesis, metastasis, and tumor proliferation, which was revealed by the decrease in the liver levels of VEGF, MMP-2.9, and cyclin D1 mRNA, respectively.
In summary, compared to using celastrol alone, the combination of metformin and celastrol appears to be more effective in treating HCC by blocking the NLRP3 inflammasome and NFκB signaling[14]. Surgery is the primary treatment option for patients in the early stages of malignancy. However, if surgical resection or radiofrequency therapy is not feasible, patients can be treated with arterial chemoembolization[15], anticancer drug and lipiodol emulsion[16], or drug-eluting beads[17]. Liver transplantation is a radical curative surgery that is commonly used as a standard treatment for HCC (hepatocellular carcinoma) using the Milan criteria[18]. However, patients who require liver transplantation often face a shortage of donors and the progression of their cancer stage while waiting for a donor[19]. In cases where other treatments fail, sorafenib (Nexavar), a kinase inhibitor drug, might be prescribed for patients. Sorafenib is approved to treat renal cell carcinoma (RCC), unresectable HCC, FLT3-ITD positive AML, and radioactively iodine-resistant advanced thyroid carcinoma. It exhibits activity against numerous protein kinases, including VEGFR, PDGFR, and RAF kinases. Preventing HCC and conducting thorough screening for high-risk populations are therefore essential[19,20]. HCC is a primary liver cancer that primarily affects people with cirrhosis and chronic liver disease. However, Approximately 25% of patients have no history of cirrhosis or risk factors[18]. Vaccination and antiviral therapy can have a positive effect in preventing the development of cirrhosis. Nevertheless, if antiviral therapy is delayed until cirrhosis develops, its preventive effect will be reduced[19]. Interferon therapy is also ineffective in reducing the risk of HCC. There are other agents, such as metformin, retinoids, and propranolol, that may be effective in reducing HCC but require further prospective trials[10,20]. Thus, the current study set out to find out whether metformin could aid in reducing HCC caused by the hepatitis B and C viruses.
MOLECULAR MECHANISMS OF HBV IN THE DEVELOPMENT OF HCC
Hepatitis B virus
The Hepadnaviridae family of enveloped DNA viruses includes HBV, which has partially double-stranded relaxed circular DNA (rcDNA). Globally, about 300 million people have HBV infection, which is a leading cause of cirrhosis development and its complications[21,22]. HBV genome comprises four genes (C, S, X, and P). In addition, the Hepatitis B X protein (HBx) plays a critical role in the development of HCC at the molecular and cellular levels[23]. One important component of the HBV-related HCC mechanism is HBV integration into the host genome. HBV is among the most important risk factors for liver cancer development. Numerous aspects of the host’s liver cells may be impacted by the infection, resulting in inflammation of the liver that may develop into chronic hepatitis, cirrhosis, and possibly HCC. Genomic stability, HBV gene expression, and host gene expression profiling can all be altered by HBV DNA integration into the host genome. Early in the infection process, this integration may take place. The host genes close to the integration sites may be impacted by the integrated fragment, which may ultimately contribute to carcinogenesis. The integrated fragment may express full-length or shortened HBV proteins. Interestingly, a significant proportion of HBV-related HCC can be seen in non-cirrhotic liver. This suggests that HBV integration into the host genome can lead to HCC even in the absence of cirrhosis[24]. Furthermore, persistent HBV infection of the liver cells can lead to HCC, cirrhosis, fibrosis, or chronic hepatitis B. There are several HBV-related risk factors for HCC, including the level of HBV DNA load, genotypes of HBV, and full-long or truncated proteins of HBV. Overall, the integration of HBV into the host genome plays a crucial role in the development of HCC. It can occur early in the infection and can lead to HCC even in non-cirrhotic livers. This highlights the importance of early detection and treatment of HBV infection to prevent the development of HCC[25]. Several known mechanisms play a crucial role in HBV-induced HCC, which are discussed below.
HBV-induced HCC mechanisms
Signaling pathways (including Hippo, Ras-Raf-MAPK, c-Src, PI3K-Akt, NF-κB, JAK-STAT, Wnt/β-catenin, TGF-β and p53)
The Hippo signaling pathway is essential for controlling stem cell self-renewal, apoptosis, and cell division[26]. Furthermore, Yes-associated protein (YAP) is a downstream effector of this pathway and is considered to be a critical human oncogene. The Hippo pathway regulates YAP function, and the module phosphorylates YAP on serine residues, restraining YAP activity[27]. Research on mice has demonstrated that overexpression of YAP stimulates the growth of liver cancer by controlling the transcription of specific target genes like c-myc, Ki-67, SRY-Box 4 (SOX4), H19, and α-fetoprotein (AFP)[28]. Additionally, overexpression of YAP in transgenic mice increases liver size and eventually leads to cancer[29]. Zhang et al. discovered that YAP was overexpressed in hepatoma HepG2.2.15 cell line, HCC samples, and liver cancer tissues from HBx-transgenic mice[30]. Furthermore, a recent study found that the expressions of the HBx and YAP proteins are linked to metastasis and a poor prognosis[31].
By phosphorylating apoptosis-regulating factors such as Bad, Bim, Mcl-1, caspase 9, and the contentious Bcl-2, the Ras/Raf/MAPK cascade contributes to cell-cycle regulation, cell differentiation, and apoptosis[32]. This pathway contributes to HCC development in a number of ways. For example, overexpression of Raf kinase is seen in the majority of HCC cases, and the Ras gene is mutated in approximately 30% of HCC cases. Furthermore, overexpression of several upstream growth factors, including transforming growth factor-α (TGF-α), platelet-derived growth factor-β (PDGF-β), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) has been observed in HCC[33-35]. Studies have shown that HBx promotes liver cancer metastasis by activating the ERK and p38 MAPK signaling pathways[36,37]. Another study by
c-Src is a cytoplasmic non-receptor tyrosine kinase that mediates intracellular signal transmission by binding to various proteins in the Src family of kinases[40]. By controlling angiogenesis, migration, invasion, apoptosis, proliferation, and angiogenesis, Src contributes significantly to the development of tumors and increases the progression of cancer[41]. According to a Yang et al. study, c-Src plays a critical role in the development of HCC, and a poor prognosis is associated with its elevated expression[42]. During developmental morphogenesis, a cellular process known as the epithelial-mesenchymal transition (EMT) gives stationary epithelial cells the capacity to migrate and invade[43]. In HCC cells, HBx protein may induce EMT by activating c-Src[44]. The PI3K/AKT pathway is crucial for controlling the motility, growth, proliferation, and metabolism of cells[45]. Once activated, the PI3K/AKT pathway increases the expression of matrix metalloproteinases (MMPs) and snail transcriptional for EMT induction[46]. Wang et al. reported a significant up-regulation of PI3K/AKT signaling in HCC Huh7 cells[47]. Multiple studies have also demonstrated that HBx can activate the PI3K/AKT pathway, promoting cell proliferation in vitro[48-51].
The transcription factor nuclear factor kappa B (NF-κB) is essential for both innate and adaptive immunity as well as inflammation. It acts as a central link between hepatic injury, fibrosis, and HCC[52]. Research has indicated that HBx can trigger NF-κB via multiple unique signaling pathways[53]. Interleukin 6 (IL-6) is among a group of cytokines and growth factors that are produced when NF-κB signaling is activated in Kupffer cells. The most significant cytokine in determining whether HCC will survive is IL-6[54]. In this regard, Quétier et al. indicated that HBx can promote the expression of IL-6 in hepatoma cells[55]. Another study revealed that HBeAg can cause HBV replication and sustain persistent viral infection by suppressing NF-κB activation[56]. It is true that NF-κB has two sides. HBV causes hepatocyte inflammation through the NF-kB pathway dysregulation, but it also inhibits antiviral immune responses.
Important downstream pathways of interferon (IFN) receptors that promote the synthesis of IFN-stimulated genes (ISGs) include the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Numerous studies have shown that this pathway is often deregulated in cancer, including HCC. The pathway plays a vital role in IFN-mediated inhibition of HBV replication[53]. According to
The Wnt/β-catenin signaling pathway plays a role in multiple developmental processes, such as migration, homeostasis, apoptosis, and cancer linked to inflammation[59]. Alterations in the Wnt/β-catenin activity have been linked to liver damage, inflammation, and the development of HCC[60]. The pathway activates cyclooxygenase (COX)-2, which enhances the inflammatory response[61]. COX-2 plays a crucial role in producing matrix metalloproteinases (MMPs) by liver cells, which are essential for tumor progression and metastasis. Studies have shown that HBx is significant in modulating and inducing the canonical Wnt/β-catenin signaling pathway[62-64].
Transforming growth factor-beta (TGF-β) is a cytokine that controls immune cell function and plays a role in angiogenesis, immunoregulation, wound healing, and cancer[65]. The dysregulation of TGF-β is a key factor in the development of HCC[66]. Recent research has demonstrated that the coexistence of HBx and TGF-β1 is associated with the malignant transformation of hepatic progenitor cells (HPCs), and that the degradation of protein phosphatase magnesium-dependent 1A (PPM1A) induced by the HBx protein is a novel mechanism for the over-activation of the TGF-β pathway[67]. Dong et al. showed that HBx and TGF-β1 coexist in the malignant transformation of hepatic progenitor cells (HPCs)[68]. The tumor suppressor protein P53 (TP53) plays a crucial role in maintaining genomic integrity[69]. Yang et al. found that TP53 mutations were the most common gene change in HCC and HBV-related HCC patients using bioinformatics; this frequency can increase[70]. Research has indicated that there are direct interactions between HBx and p53 both in vivo and in vitro[69]. Chan et al. found that HBx modulates p53 genes through post-translational modifications[71]. According to a different study, p53 may function as an inhibitor of HBV replication[69] [Figure 2].
Figure 2. Molecular mechanisms of HBV-related HCC.
Epigenetic and genetic alterations
Heritable modifications in gene expression that do not entail modifications to DNA sequence are referred to as epigenetics[72]. The HBx protein induces hyper or hypo-methylation and histone acetylation or de-acetylation of tumor-related genes, affecting epigenetic changes[73,74]. These alterations may cause the genome of the host cell to become unstable, which would cause oncogenes and tumor suppressor genes to express abnormally[75]. Furthermore, the modifications facilitate the virus’s evasion of immune monitoring and advance the course of the illness from inflammation to tumor development[76]. Long noncoding RNAs (lncRNAs) are a class of noncoding RNA with a transcript length of > 200 nucleotides[77]. Via particular cell signaling pathways, LncRNAs affect HCC invasion, migration, and proliferation. They also cause HCC therapy resistance[78]. Several studies have shown that particular lncRNAs can be directly or indirectly dis-regulated by the HBx protein[79-81] [Table 1].
Role of lncRNAs in HBV-induced HCC
| LncRNAs* | Expression status |
| HEIH, UCA1, Linc00152, PVT1, DLEU2, HOTTIP, HOTAIR, HULC, MALAT1, Linc01152, ZEB2-AS1, HBx-LINE1, DBH-AS1, PCNAP1, WEE2-AS1, Unigene 56159, H19, n335586, HUR1, SAMD12-AS1, MVIH, Ftx | UP |
| H19, DREH/hDREH, LncRNA-6195 | Down |
A family of small noncoding RNAs known as microRNAs (miRNAs) controls translational regulation of gene expression[82]. Researchers have shown that in HBV-induced HCC, HBx dysregulated some miRNAs
Role of miRNAs in HBV-induced HCC
| miRNAs | Expression status |
| miR-155, miR-181a, miR-148a, miR-21, miR-221, miR-3928v | UP |
| miR-34, miR-122, miR-15b, miR-122, miR-375 | Down |
Autophagy
Autophagy (self-eating) is a lysosome-dependent cellular degradation program that acts as an adaptive cell response to stimuli or stresses to maintain homeostasis and prevent nutritional, metabolic, and infection-mediated stresses[86]. However, autophagy plays a dual role in the development of liver cancer. On the one hand, it inhibits the expression of tumor suppressors and contributes to chemoresistance in HCC cells. On the other hand, it activates several signaling pathways, such as the PI3K-AKT-mTOR, AMPK-mTOR, EGF, MAPK, Wnt/β-catenin, p53, and NF-κB pathways, which can promote liver cancer development[87,88].
Reactive oxygen species
Reactive oxygen species (ROS)-induced activation of tumor suppressor genes and proto-oncogenes triggers the activation of signal transduction pathways, which in turn plays oncogenic roles[92]. ROS is known to have a crucial role in the progression of liver disease, regardless of its underlying cause[93]. Chronic viral infections can exacerbate ROS production, causing oxidative stress in host cells[94]. HBV modifies mitochondrial function to generate ROS, and it has been demonstrated that the HBx protein increases mitochondrial ROS production[95,96].
MOLECULAR MECHANISMS OF HCV IN THE DEVELOPMENT OF HCC
Hepatitis C virus
A major cause of liver cirrhosis and hepatocellular carcinoma, affecting 71 million people globally, is the hepatitis C virus (HCV)[97]. HCV can lead to acute and chronic infections, with acute infection affecting 20%-30% of adults, while chronic infection occurs in 70%-80% of infected individuals, causing prolonged liver damage[98]. The genome of the virus codes for several different proteins, including structural proteins like core, E1, and E2, and non-structural proteins such as p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B[99]. Presently, there are no vaccines available for HCV, but antiviral therapies are used to cure HCV-infected patients[100]. The molecular mechanisms behind HCV-induced hepatocellular carcinoma are complex, involving several factors, such as oxidative stress, epigenetic and genetic alterations, steatosis, proliferation, and apoptosis[101].
HCV-induced HCC mechanisms
Oxidative stress
A major factor in the emergence of both chronic liver disease and liver cancer is oxidative stress. Oxidative stress can produce ROS, which can activate inflammatory genes and raise the risk of cancer[101]. Patients with cirrhosis are more likely to develop liver cancer because chronic hepatitis C infection is linked to elevated levels of oxidative stress[102]. Recent studies have shown that ROS production is initiated by the immune system in chronic hepatitis[103]. Moreover, research by Farinati et al. revealed that HCV infection leads to higher levels of ROS production compared to other hepatitis viruses[104]. Additionally, research has shown that the HCV core protein raises oxidative stress levels in the liver[105]. Several studies have shown that various proteins of HCV, including E1, E2, NS4B, NS5A, and NS3, are involved in inducing oxidative stress[106-108]. The NS5A and NS3 proteins are known to cause oxidation of mitochondrial glutathione, which leads to an increase in ROS in the mitochondria. Oxidative stress is caused by the translocation of transcription factors into the nucleus of nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT-3)[109-111]. Furthermore, p38 MAPK (mitogen-activated protein kinase), JNK (c-Jun N-terminal kinase), and AP-1 (activator protein-1) are activated by NS5A to cause oxidative stress[112].
Epigenetic and genetic alterations
Studies have shown that epigenetic alterations can contribute to initiating and promoting HCC. Researchers have reported that histone modifications, DNA methylation, and noncoding RNA (ncRNA) expression are associated with the progression of HCC[113]. It is thought that HCV’s carcinogenic potential is indirectly related to epigenetic changes, which occur when oncogenic genes are activated by hypomethylation and tumor suppressor genes are inactivated by hypermethylation[114]. Methylation disorders have the potential to cause HCC by inactivating tumor suppressor genes and activating carcinogenic genes. According to
Methylation disorders in HCV-related HCC
| Methylation status | Types genes | Genes* |
| Hypermethylation | Tumor suppressors | RASL1, EGLN3, CSMD1, CDKN2A, BCORL1, SFRP1, P73, ZNF382, RUNX3, LOX, RB1 |
| Hypomethylation | Oncogenic | OTX2, IGF1R, SNCG, ZBTB16, FOXA1, HNF4A, CEBPA |
Moreover, the development of HCC is significantly influenced by histone modifications, including methylation, acetylation, phosphorylation, sumoylation, and ubiquitination. Overexpression of Jumonji AT-rich interactive domain 1B/lysine-specific demethylase 5B (JARID1B/KDM5B), for example, has been shown to promote HCC cell proliferation in HCV-induced HCC by controlling the expression of
Role of lncRNAs in HCV-induced HCC
| LncRNAs* | Expression status |
| HOTAIR, HULC, PVT1, LINC01419, BC014579, AK021443, RP11-401P9.4, RP11-304 L19.5, BC017743, BC043430, PCNA-AS1, UFC1, ZEB1-AS1, hDREH, UCA1, WRAP53, MALAT1, HEIH | UP |
| AF070632, CTB-167B5.2, aHIF, PAR5, LINC01152, TMEVPG1 | Down |
Additionally, there is evidence suggesting a connection between hepatocellular carcinoma (HCC) and the disruption of microRNAs (miRNAs) regulation[120-122]. Research indicates that HCV, miRNAs, and metabolic pathways in hepatocytes interact closely, leading to the development of liver disease. In a survey conducted by Diaz et al., they identified 18 miRNAs that were specifically expressed in HCV-induced HCC
Role of miRNAs in HCV-induced HCC
| miRNAs | Expression status |
| mir-1269, mir-224, mir-452, mir-224-3p, mir-224-5p, mir-221 | UP |
| mir-214, mir-195, mir-130a, mir-125a-5p, mir-125b-5p, mir-424-3p, mir-139-3p, mir-139-5p, mir-199b-3p, mir-199a-3p, mir-199a-5p | Down |
Steatosis and insulin resistance
An accumulation of lipids within hepatocytes, called hepatic steatosis, is a significant risk factor for HCC development[123]. However, HCV infection frequently leads to hepatic steatosis[124]. This condition is common in HCV patients (ranges from 40%-86%) and can be caused by various factors such as viral factors (HCV genotype3), host factors (overweight, insulin resistance, diabetes mellitus, hyperlipidemia, and alcohol consumption), and drug therapy (corticosteroids, amiodarone, methotrexate, among others)[125]. Steatosis is strongly associated with higher fibrosis scores and severe histological injury in HCV patients. It is currently unknown exactly how HCV infection could lead to the development of parenchymal steatosis.
The enzyme known as microsomal triglyceride transfer protein (MTP) is essential to the formation of very low-density lipoprotein (VLDL), the blood-borne lipid-transporting protein. However, the activity of MTP can be inhibited by two proteins found in HCV - core protein and NS5A. This inhibition leads to the accumulation of triglycerides in cells, which causes steatosis[126,127]. In addition, HCV core protein has been shown to cause mitochondrial dysfunction by inducing the overproduction of ROS and attenuating some of the antioxidant systems[128,129]. This can be detrimental to the liver as it needs healthy mitochondria to function correctly.
Interestingly, peroxisome proliferator-activated receptor alpha (PPAR-α) can help alleviate steatosis[130,131]. However, in the presence of mitochondrial dysfunction, PPAR-α may exacerbate steatosis instead of alleviating it. HCV NS5A and core protein can also induce insulin resistance, which further worsens steatosis. It is worth noting that the genotype of HCV can also play a role in inducing steatosis. Genotype 3, in particular, has the highest association with steatosis[126].
Proliferation and apoptosis
Normal development and tissue-size homeostasis depend on the coordination and balance of two fundamental cellular processes: cell proliferation and apoptosis. There is evidence that cancer may result from these processes being disrupted[132]. Cyclin-dependent kinases (CDKs) and cyclins are one of the most important proteins involved in controlling cell division in response to extracellular and intracellular signals. Furthermore, inhibitors such as pRb, E2F-1, DP-1, p107, and p130 regulate the cell cycle[133]. Since viruses alter CDK function to promote viral replication, CDKs play a crucial role in viral infections[134].
To maintain tissue-size homeostasis and normal development, cell proliferation and apoptosis must be balanced and coordinated. Evidence suggests that disrupting these processes can cause cancer[132]. Cyclin-dependent kinases (CDKs) and cyclins are among the most important proteins involved in controlling cell division in response to extracellular and intracellular signals. Additionally, regulators such as pRb, E2F-1, DP-1, p107, and p130 manage the cell cycle[133]. CDKs also play a significant role in viral infections, as viruses modify CDK function to favor viral replication[134].
Some viral infections can cause changes in cell proliferation due to the actions of viral proteins on CDKs or cyclins, which can lead to cancer development. Researchers have studied the effects of HCV proteins, particularly the core protein, on the cell cycle profile and related molecules. Evidence shows that HCV proteins can activate cyclin/Cdk complexes and stimulate G1/S transition. HCV core protein can increase cyclin E and Cdk2, while HCV NS2 protein can activate cyclin D/Cdk4 and stimulate the expression of cyclin E[135,136]. The cyclin-dependent kinase inhibitor p21/Waf, a potential tumor suppressor, plays a critical role in cell cycle progression. HCV core protein can regulate the expression of p21/Waf by binding to p53 and Rb, which are both involved in cell cycle control[137]. HCV proteins also target the retinoblastoma (Rb) protein.
One transcription factor that is essential for enabling cells to move into the S-phase of the cell cycle is called Rb. However, recent studies have shown that the HCV NS5B protein can negatively regulate Rb levels. This causes the activation of E2F-responsive genes, which can stimulate cell cycle progression[138]. In order to keep tissues healthy, apoptosis is required to eliminate senescent cells that have been harmed by a variety of conditions, such as viral infections. However, it has been discovered that HCV proteins obstruct apoptosis signaling pathways[139]. Bcl-2 and Bcl-xL proteins also play a crucial role in apoptosis, and changes in their expression can contribute to the development of cancer[140]. HCV core protein can block apoptosis by promoting the expression of Bcl-xl[141].
Similarly, by inhibiting different caspase cascade components, HCV non-structural proteins such as
Figure 3. Molecular mechanisms of HCV-related HCC.
METFORMIN
HCC, a type of liver cancer, can be caused by several factors, such as alcohol consumption, obesity, and type 2 diabetes (T2D) in developed countries. Hepatitis B and C viruses, however, continue to pose a serious threat to international health since they can cause liver conditions like cirrhosis and HCC[144]. Several cohort studies have shown that metformin, a medication for diabetes, can cause metabolic issues like insulin resistance and diabetes in people infected with HBV and HCV[145]. Research on the effectiveness of metformin on viral hepatitis is still ongoing. HCC is a deadly condition with a dismal prognosis for cancer sufferers, and the treatments currently available are associated with several issues. Metformin is derived from a naturally occurring compound called galegine, found in the plant Galega officinalis[146]. Since the 1950s, 1,1-dimethylbuguanide hydrochloride, or metformin, has been widely accepted as a first-line antidiabetic medication. However, it also seems to have anti-cancerous effects[147].
Metformin has been found to have anticancer effects by altering various signaling pathways responsible for cellular proliferation, apoptosis, and metabolism. It regulates the synergistic activity of AMPK, GSK-3, and PPAR, which leads to its anti-angiogenic, anti-invasive, and anti-proliferative properties. These effects have been observed in pancreatic cancer and glioblastoma multiforme. Metformin has a wide range of tissue effects, including on the liver, skeletal muscle, colon, pancreatic, breast, prostate, endometrium, and ovaries. Its use has been associated with reducing the incidence and mortality of various malignancies[148-151]. Additionally, metformin is considered to be a useful drug in the treatment of polycystic ovarian syndrome, cardiovascular disease, and even anti-aging[152]. In cultured and living cells, Metformin slows tumor growth by inducing apoptosis, stopping the cell cycle in some malignancies, and activating caspase 3. Scientists are now exploring how metformin can be used to prevent and treat HCC[153,154].
Worldwide, cirrhosis and CLD are highly prevalent. The incidence of chronic liver disease (CLD) has decreased globally as a result of hepatitis B and C vaccine, screening, and antiviral treatment programs; however, these advancements are at risk due to concurrent increases in injectable drug use, alcohol abuse, and metabolic syndrome. While encouraging recent developments have been made in the treatment of all stages of HCC, more needs to be done to slow the rise in HCC mortality, including better early detection, more use of HCC surveillance, and fair access to HCC medicines[155-157].
Metformin usage in cirrhotic patients has been found to reduce the occurrence of HCC. Metformin affects cancer cells by targeting the mitochondria and blocking mammalian targets of rapamycin (mTOR) and insulin-like growth factor (IGF) signaling, which reduces carcinogenesis[158]. When metformin enters the cell, it inhibits the mitochondrial electron transport system, reducing cellular adenosine triphosphate (ATP) and increasing the adenosine monophosphate AMP/ATP ratio[159]. Tregs are a subset of T lymphocytes that regulate the immune response by stopping the proliferation and cytokine production of effector T cells. In the liver and other organs, they are essential for peripheral self-tolerance and immunological homeostasis[160]. One important component of the Tregs’ inhibitory effect is the expression of the transcription factor forkhead box protein 3 (FOXP3)[161]. An increasing body of research indicates that this particular cell type is involved in the pathogenesis of several diseases, such as HCC, chronic viral liver problems, and autoimmune diseases[162]. Consequently, innate immune cells (monocytes/macrophages, DC cells, NK cells) and adaptive immune cells (CD4+, CD8+ T cells) are reduced in chronic HBV infection. Therefore, HBV stimulates immunosuppressive cells including MDSC, NK-reg, and T-reg cells to establish an immunosuppressive cascade that aids in chronic and persistent viral infection through inhibitory substances such as PD-L1, PD-1, and IL-10[163]. Similarly, a higher frequency of CD4+CD25+ Tregs in the blood and liver has been seen in patients with chronic HCV infection. These findings collectively demonstrate that Treg-driven inhibition of the host immune response is a hallmark of immunological chronic HBV and HCV infections[164,165]. Thus, metformin enhances the immunological response of CD8
Metformin activates the AMPK-mTOR signaling pathway and causes autophagy in human liver cancer cells[167]. Compared to other medications, pharmacokinetics is a crucial aspect of metformin[168]. It is more efficiently distributed in liver cells than Rosiglitazone and Simvastatin[165]. Choi and Roberts claim that taking statins and metformin to prevent HCC may be extremely beneficial for high-risk people[169]. Metformin use is independently linked to a lower incidence of HCC and liver-related death/transplantation in individuals with T2D who have HCV cirrhosis, according to a study by
Arterial chemoembolization (TACE) is the standard treatment for incurable HCC[173]. When local ablation is not practical, TACE is frequently employed as a locoregional therapy for early HCC[174]. TACE results in HCC cell death via ischemia and an increase in the local concentration of cytotoxic medications. However, neo-angiogenesis of residual HCC may result from TACE-induced ischemia because of elevated local concentrations of HIF-1α and vascular endothelial growth factor[175]. Patients using metformin in addition to transarterial chemotherapy-embolization who have hepatocellular carcinoma have a better prognosis[176]. According to a Chen’s study, exposure to metformin was associated with a favorable outcome when TACE was selected as the initial course of treatment for a single HCC[174]. In actuality, metformin significantly lowers the risk of recurrence after TACE and extends long-term survival for HCC patients with T2 diabetes[174]. However, not every patient reacts favorably to this process. Even in patients who respond well to TACE, refractoriness or failure affects the course of the disease[177]. Thus, to improve the prognosis of patients with HCC following TACE, accessible and effective adjuvant therapies are required[173]. Recent research indicates that metformin, aspirin, and statins may prevent HCC from spreading. The study findings demonstrate that co-treating HepG2 cells with metformin and aspirin is more effective at stopping the cell cycle in the G2/M phase and inducing apoptosis in a caspase-dependent manner by downregulating the expression of the pAMPK and mTOR proteins[178]. Aspirin can help prevent malignancies such as hepatocellular carcinoma when taken in small quantities. According to Luca Ielasi’s observations, patients receiving aspirin and sorafenib concurrently as antineoplastic treatment had better results than those not receiving aspirin[179]. Several mechanisms, both reliant and independent on cyclooxygenase (COX), have been postulated to explain this effect, given that HCC is a chronic inflammation-related carcinogenesis. It has been suggested that aspirin might be a viable treatment for HCC because it is marked by high levels of COX-2[179,180].
A cohort study involving 100 diabetic patients with HCV cirrhosis found that the use of metformin was significantly linked to a decrease in HCC incidence and a reduced need for liver transplantation or liver-related death[170]. In another study, Kasmari et al. analyzed the US insurance database. They discovered that even after excluding individuals with concurrent cirrhosis, NAFLD, and non-alcoholic steatohepatitis (NASH), the incidence of HCC in T2DM patients treated with metformin was still significantly lower[181]. The research conducted by Lai et al. 32 revealed that after accounting for factors such as sex, age, and comorbidities, individuals with T2D, HBV, and HCV who were on metformin exhibited the lowest HCC hazard ratio (HR) at 0.49 (95%CI: 0.37-0.66)[182]. The study cohort included a total of 71,824 patients with HBV infection. The findings indicated that the use of either metformin or statin was linked to a decreased incidence of cancer. The most significant reduction was observed in patients taking both statin and metformin[183]. Among 191 patients in the US diagnosed with T2D and histologically confirmed NASH along with fibrosis, the use of metformin showed a significant association with a decreased risk of HCC and a lower rate of all-cause mortality and transplantation[184]. The use of metformin significantly lowered the risk of HCC following successful antiviral treatment in individuals with diabetes and chronic HC. A straightforward risk stratification model, which includes cirrhosis and non-metformin use in diabetes mellitus, could forecast long-term outcomes in individuals with CHC after achieving sustained virological response (SVR)[185]. We have mentioned a summary of the studies in Table 4.
METFORMIN AND HBV/HCV-RELATED HCC
Metformin, as an antidiabetic agent, has been one of the main treatment options for type 2 diabetes patients[186]. This drug is not only commonly used as the first line of treatment in these patients, but its potential anticancer properties in cancers such as the liver have also attracted the attention of researchers[186]. This drug reduces the risk of liver cancer in these patients by treating their diabetes because it has been demonstrated in laboratory and clinical settings that diabetic patients are up to 7.1 times more likely than other people to develop liver cancer. Molecular target therapy is a new method for treating various cancers, including HCC. Researchers are interested in this method and hope it will reduce cancer progression and improve patient survival. Metformin’s anticancer molecular mechanisms involve various signaling pathways such as autophagy and apoptosis, hyperinsulinemia, and fatty liver accumulation, as well as cancer microenvironment factors, including cytokines and factors that contribute to cancer progression. This article discusses the roles of these factors in HCC, their interactions with hepatitis B and C viruses, and how metformin can help reduce HCC.
AMP kinase acts as a metabolic tumor suppressor and serves as an energy sensor in all mammalian cells. In cancer cells, this factor is activated by abnormal conditions like hypoxia and glucose deprivation, which cause an increase in the AMP/ATP or ADP/ATP ratio. By regulating cell energy levels, it interacts with mechanisms such as autophagy, apoptosis, and the cell cycle to play an important anticancer role[187]. Its activities are mainly observed in tissues like muscle, fat, and liver. Some reports suggest the high significance of this factor in the survival of HCC patients, as the dysfunction of AMPK has been shown to cause cancer progression through an uncontrolled cell cycle, cell cycle progression, survival, migration, and invasion of cancer cells using various tumorigenic molecules and pathways[188]. However, despite its inhibitory role in hepatitis C virus replication, activating AMPK via drug treatments is a novel strategy for treating HCV-related diseases, including HCC cancer[189].
Metformin is the treatment of interest for researchers in stimulating AMPK activation in HCC patients via an LKB1-dependent mechanism[190]. Furthermore, to increase its anticancer efficacy, this drug, through the activation of AMPK, prevents the activating of the NF-κB signaling pathway by stimulating the expression of IκBα. Because activation of this signaling pathway can reduce the anticancer effects of metformin by ectopic expression of P65 or overexpression of an undegradable mutant form of IkBa, respectively[191], treatment with metformin to activate AMPK, reported in vivo and in vitro, can reveal the drug’s potential to treat HCC patients with HCV. Studies have also shown that metformin, when used in combination with other drugs such as celastrol, aspirin, and celecoxib, among others, can be more effective in preventing HCC [Table 6][178,186,192-194].
The effects of various metformin and other treatment combinations on patients with HCC
| Treatments | Effect | Ref. |
| Aloin | Aloin and metformin are administered concurrently to increase the antitumor effect. This is accomplished by blocking HCC’s growth and invasion and activating the PI3K/AKT/mTOR pathway to cause apoptosis and autophagy | [194] |
| Sirolimus | Reduced levels of phosphorylated PI3K, AKT, AMPK, and mTOR in patients with HCC related to hepatitis B virus enable sirolimus and metformin to inhibit HCC growth and increase long-term survival additively | [186] |
| Celastrol | Celastrol and metformin have new combination antitumor effects by suppressing NFKB, improving the apoptosis pathway, and reducing TNF-α and IL-6 levels in murine HCC induced by diethylnitrosamine | [14] |
| Sorafenib | By focusing on the mTOR pathway, the combination of metformin and sorafenib inhibits HCC growth and promotes autophagy | [193] |
| Aspirin | A potential therapeutic approach for HCC is targeting AMPK, mTOR, and β-catenin by combining metformin and aspirin therapy | [178] |
| Celecoxib | Celecoxib and metformin therapy reduce the phosphorylation of mTOR, which inhibits HCC growth to a greater extent than both therapies | [192] |
Studies have mentioned various reasons for the role of NF-κB in cancer progression, highlighting the importance of metformin’s suppression of this factor. Although NF-κB[195] may have a dual role in suppressing tumorigenicity during the early stages of tumor development or contributing to tumorigenesis in the later stages due to mutations[195], inappropriate activation of this pathway has been reported in various diseases and cancers, including liver cancer[196]. As a result, several studies have identified it as a crucial link between liver damage, fibrosis, and liver cancer. Therefore, targeting NF-κB can be effective in the prevention or treatment of liver fibrosis and liver cancer[197].
On the other hand, the up-regulation of this pathway by hepatitis B and C viruses has been reported as the main cause of liver cancer when damage and inflammation increase and eventually lead to cancer. As a result, this pathway, along with STAT3, can play a key role in the development of inflammation and liver cancer, which can be an important step in the development of liver cancer by affecting the production of inflammatory cytokines such as IL6[198] bTheIL-6/STAT3 signaling pathway is one of the critical pathways involved in HCC progression and plays a vital role in different stages of cancer, including HCC cell initiation, development, invasion and metastasis[199].
The mTOR protein is a type of serine protease that forms the main component of mtor1 and mtor2 complexes. These complexes are essential for controlling a number of biological functions, including autophagy, transcription, protein synthesis, growth and proliferation of cells, and survival[200,201]. As a key signaling pathway, this protein, located upstream and downstream of other molecules, can significantly impact the metabolism and physiology of the mammalian body[202]. However, its regulation is often disrupted in certain diseases, including cancer. Specifically, upregulating and activating mtor1 can contribute to cancer hallmarks such as cell growth, metabolism re-programming, proliferation, and apoptosis inhibition. This upregulation has also been observed in HCC cancer tissue samples compared to adjacent cirrhosis tissue, further confirming its role in HCC proliferation and spread[203]. HCV and HBV are known to increase mTOR expression and activity by means of their NS5A (HCV) and pre-S1, HBx (HBV) proteins. This effect occurs via PI3K/Akt and Akt/mTOR signaling pathways, which ultimately leads to the progression of HCC cancer[204].
These oncogenic roles of mTOR have caused it to be targeted by metformin in the direction of the anticancer role of this drug, including in HCC cancer. This drug suppresses mTOR in HCC cancer in different ways, such as activating AMPK and preventing the phosphorylation of PI3K and AKT; the activation of AMPK located upstream of mTOR can have an inhibitory effect on mtorc1. By activating AMPK located upstream of mTOR, it inhibits mTORc1 activity. In addition, metformin activates autophagy through the AMPK/mTOR pathway. It also affects the PI3K/Akt pathway by preventing the phosphorylation of PI3K, AKT, and mTOR, leading to the prevention of their activity and thus activating autophagy. These effects of metformin on AMPK and PI3K/Akt pathways ultimately prevent the HCC process[194].
Most studies suggest that autophagy plays an anticancer role in liver cancer by preserving cellular homeostasis in normal hepatocyte cells despite its dual role in various cancers. HBV and HCV can activate autophagy to increase replication, but this process is incomplete. The viruses take over only the initial stages of autophagy while avoiding the final and destructive stages of this mechanism. Therefore, the increase in the level of lc3-ll, which indicates the number of phagosomes, and the decrease in the level of p62, a marker for autophagic activity that destroys protein aggregates, are indicators of metformin-induced autophagic activity and autophagic flux in HCC, particularly in the middle and late stages[167].
The PI3K, AKT, and mTOR pathways play a significant role in metformin-induced apoptosis in HCC. Metformin prevents the activity of this pathway, which is upstream apoptosis, thereby eliminating HCC cells[194]. Disruption of apoptosis, a liver physiological mechanism that removes excess cells during growth and regeneration stages, paves the way for the development of liver and bile duct cancers. The regulation of many apoptotic factors, including p53 in HCC, is disrupted, leading to cancer cell resistance to apoptosis. The dysregulation of apoptosis factors in HCC cancer is often caused by HBV and HCV viruses. The NS5A protein of HCV and the HBx oncoprotein of HBV can disrupt the apoptosis signaling pathway, leading to HCC development[205,206]. Although these two viruses affect different targets to suppress apoptosis, the most common ones are the apoptotic factor p53 and the PI3K/Akt signaling pathway[205,206]. On the other hand, p53 is an essential tumor suppressor that is found to be mutated in most human cancers, including HCC. It is reported to be the most frequently mutated gene in liver cancer, with more than 45% of HBV-related liver cancers and 13% of HCV-related liver cancers showing mutations in this gene. Additionally, this gene has different isomers, such as p63 and p73, whose biological functions are similar to p53. In cases where p53 is mutated, especially p73, which is rarely mutated in human tumors, it can be a suitable anticancer replacement for p53. Various studies have shown that these genes can be important targets of metformin in reducing tumorigenesis in various cancers. The metformin/AMPK/p53, p63, and p73 pathways can serve as a new strategy in the treatment of HCC and prove to be vital in achieving this goal[207]. Wnt/β-catenin is a signaling pathway that is activated in 40% to 60% of HCC cancers. This pathway regulates cellular processes such as initiation, growth, survival, migration, differentiation, and apoptosis of HCC. However, when mutations in Wnt signaling components and hypoxia inappropriately activate this pathway, it can also promote the progression of chronic HCV/HBV infection to cancer, making it one of the most common causes of HCC. In HCC tumors associated with HCV, an increase in CTNNB1 gene mutations occurs as one of the components of the Wnt/β-catenin signaling pathway. In tumors associated with HBV, an increase in CTNNB1 gene mutations in Axin1 as a negative regulator of the Wnt/β-Catenin cascade has also been reported[208]. The activity of this pathway in chronic HCV infection promotes virus-induced cell proliferation and colony formation, which can be reduced by destroying β-Catenin, leading to reduced cell proliferation via an expanded G1 phase and apoptosis. A study by Lin et al. showed that metformin can significantly reduce the growth of HCC tumor cells by destroying β-Catenin through the previously mentioned mechanism[209]. T2D and hyperinsulinemia are common conditions in patients with hepatitis B and C virus-related liver cancer and cirrhosis. Increased insulin resistance in the liver, caused by the insulin/IGF-I signaling pathway or increased fat accumulation, plays a role in the development of liver cancer in these patients. Insulin-like growth factor (IGF)-1, which is part of the IGF signaling pathway, increases its level in hyperinsulinemic conditions. Through two signaling pathways, PI3K/Akt and RAS/Raf/ERK, it can contribute to the survival and growth of cancer cells[210]. In general, IGF signaling, particularly the activation of the IGF-I receptor (IGF-IR)/IGF-II pathway, plays a vital role in malignant hepatocyte transformation and the development of HCC. Although it has been reported that the expression of these two genes is higher in tumor cells than in other liver cells, in the case of IGF-II, it has been shown that its expression is much higher in the early stages of the tumor and increases cancer cell proliferation via the effect on the phosphatidylinositol 3-kinase- and Ras/mitogen pathways[211]. In addition, hypoxia-induced cancer conditions increase its expression, which in turn increases the expression of Vascular Endothelial Growth Factor A (VEGFA) and, as a result, angiogenesis[211]. To improve these two conditions, metformin may be more effective than other antidiabetic drugs in preventing liver cancer progression and cancer-related mortality.
An in vitro study conducted in 2019 showed that 400 µM of metformin can reduce the expression of IGF-II/IGF-IR, thereby reducing tumor cell proliferation and angiogenesis[211]. Metformin is absorbed in the liver through the expression of the organic cation transporter 1 (OCT1) gene. It prevents glucose production by inhibiting gluconeogenesis in the liver, leading to a decrease in insulin resistance. Poor metformin absorption can occur in people with reduced functional polymorphisms in the OCT1 gene, causing their blood sugar levels to rise[190]. Notably, the expression of the OCT1 gene plays a crucial role in the absorption and performance of metformin.
The most prevalent liver condition in the world, non-alcoholic fatty liver disease (NAFLD), is a major contributor to liver cancer in many nations. This disorder, which is closely related to type 2 diabetes, ranges from simple steatosis to NASH, which increases the risk of hepatocellular carcinoma (HCC)[212]. NAFLD is also prevalent in patients who are positive for hepatitis C virus (HCV) and is considered a prominent feature of chronic HCV infection. HCV, particularly genotype 3, causes fat deposition in the liver to optimize the conditions for its survival, which accelerates the progression of liver fibrosis and contributes to the development of liver cancer[213]. Unlike HCV, the relationship between hepatitis B virus (HBV) and NAFLD has yielded contradictory results. However, laboratory studies have demonstrated that the HBx protein can increase the formation of lipid droplets[214].
No specific drug has been approved by the FDA thus far for treating NAFLD/NASH, whether related or unrelated to HCC. Several pilot studies and clinical trials have investigated the effect of metformin on this condition. Still, so far, there has been no report on the drug’s protective effect in HCC-related NAFLD/NASH[215]. However, various retrospective observational studies have reported beneficial effects of metformin in NAFLD/NASH patients associated with HCC[215]. The drug’s positive effect can be attributed to several reasons, including the inhibition of glycogenesis and mitochondrial respiratory complex I, activation of NRF2 to reduce oxidative stress, activation of the AMPK signaling pathway to reduce fatty acid synthesis, and reduction in the number and activity of hepatic progenitor cells (HPCs) in NASH conditions. All of these cases are amplified in NAFLD/NASH conditions related to HCC, and metformin can lower the risk of HCC by acting on them[215].
The cancer microenvironment in HCC is complex and includes various factors, such as cytokines[216]. Cytokines are known to play a significant role in the relationship between cancer cells and these factors, with interleukin 22, 12, 6, TNF, and IL-1b being the most important cytokines in HCC that are targeted by metformin[14]. Active T lymphocytes secrete interleukin 22, and its overexpression and receptor are associated with promoting cell differentiation, proliferation, metastasis, progression, and poor overall survival in many cancers, including HCC. Its level also increases in liver fibrosis and advanced cirrhosis. Studies in mouse models have shown that knocking out IL22 significantly reduces the prevalence of HCC compared to wild-type mice. Zhao et al., 2021 demonstrated that metformin suppresses IL22 in the diethyl-nitrosamine (DEN)-induced HCC mouse model[216]. The results of the study’s whole transcriptome analysis and functional analysis indicated the inhibitory effect of metformin on IL22 through the stimulation of the Hippo signaling pathway[216].
Inflammation plays a significant role in the development and progression of HCC cancer. Proinflammatory cytokines such as IL-6, TNFα, and IL-1b are known to increase in HCC cancer, contributing further to inflammation and progression towards HCC[14]. TNFα is a potent factor that stimulates the NFKB pathway, which, in turn, leads to an increase in proinflammatory factors (TNF-α, IL-1β, and IL-6). Metformin not only acts as an inhibitor of the NF-κB pathway but also suppresses TNF-α/NFKB/TNF-α, IL-1β, and IL-6 pathways, preventing inflammation and the progression of HCC by inhibiting TNFR gene expression[14]. Apart from the signaling pathways discussed in the commentary, metformin targets several factors, such as opn, Rb, p21, ck19, and annexin A5, to reduce HCC. These factors play a crucial role in the development of HCC cancer and are often manipulated by HBV and HCV. Opn, a factor secreted by cancer cells, is responsible for the invasion of tumor cells and HCC cancer metastasis. An in vitro study showed that
Annexin A5 is a protein that functions as an anticoagulant and has been suggested to have anticancer properties in certain cancers, such as uterine cervical cancer, by reducing cancer cell growth and increasing cell death. A study conducted by Hassan found that metformin could increase the levels of this protein in HepG2 cells, making it a potential new adjuvant therapy for HCC cancer. Metformin causes an increase in the p21 protein, which leads to hypophosphorylation of Rb and halts the cell cycle at the G1 phase. This cell cycle mechanism is important because it controls the transition from the G1 phase to the S phase
Figure 4. Molecular mechanisms of metformin signaling pathways in cell proliferation and apoptosis.
CONCLUSION
Metformin administration to cancer patients, including those with HCC, is associated with few complications in daily clinical practice. Patients at high risk of HCC may find it attractive to use metformin for chemoprevention due to its comparatively low cost and demonstrated benefits for lowering and controlling diabetes. Therefore, metformin is safe for cancer patients as well as diabetics. More clinical trials are needed to confirm metformin’s ability to combat cancer, which would be beneficial for many cancer patients with or without diabetes.
DECLARATIONS
Author’s contribution
Wrote the main manuscript text: Shojaeian A, Mahmoudvand S, Shokri S, Nakhaie M, Amjad ZS
Prepared figures: Shojaeian A
Edited the manuscript: Shojaeian A, Boroujeni AK
All authors read and approved the manuscript.
Availability of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2024.
REFERENCES
1. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-55.
2. Mardpour S, Hassani SN, Mardpour S, et al. Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury. J Cell Physiol 2018;233:9330-44.
3. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73 Suppl 1:4-13.
4. Nahand JS, Jamshidi S, Hamblin MR, et al. Circular RNAs: new epigenetic signatures in viral infections. Front Microbiol 2020;11:1853.
5. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
6. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
7. Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A, et al. Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 2020;25:85.
8. Gao C, Fang L, Zhao HC, Li JT, Yao SK. Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int 2013;12:385-93.
9. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004;18:2285-93.
10. Saito T, Chiba T, Yuki K, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One 2013;8:e70010.
11. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 2013;36:279-87.
12. Cunha V, Cotrim HP, Rocha R, Carvalho K, Lins-Kusterer L. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review. Ann Hepatol 2020;19:232-7.
13. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750-8.
14. Saber S, Ghanim AMH, El-Ahwany E, El-Kader EMA. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother Pharmacol 2020;85:331-43.
15. Akamatsu N, Cillo U, Cucchetti A, et al. Surgery and hepatocellular carcinoma. Liver Cancer 2016;6:44-50.
16. Idée JM, Guiu B. Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol 2013;88:530-49.
17. Li H, Wu F, Duan M, Zhang G. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety. Medicine 2019;98:e15314.
18. Garrido A, Djouder N. Cirrhosis: a questioned risk factor for hepatocellular carcinoma. Trends Cancer 2021;7:29-36.
19. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013;57:399-408.
20. Chang PY, Chung CH, Chang WC, et al. The effect of propranolol on the prognosis of hepatocellular carcinoma: a nationwide population-based study. PLoS One 2019;14:e0216828.
21. Degasperi E, Anolli MP, Lampertico P. Towards a functional cure for hepatitis B virus: a 2022 update on new antiviral strategies. Viruses 2022;14:2404.
22. Kodali S, Singal AK. Potent suppression of hepatitis B virus and hepatocellular carcinoma: how long is good enough? Hepatobiliary Surg Nutr 2018;7:212-3.
24. Wang G, Chen Z. HBV genomic integration and hepatocellular carcinoma. Adv Gut Microbiome Res 2022;2022:2140886.
25. Nevola R, Beccia D, Rosato V, et al. HBV infection and host interactions: the role in viral persistence and oncogenesis. Int J Mol Sci 2023;24:7651.
26. Wang LH, Baker NE. Correction: salvador-warts-hippo pathway regulates sensory organ development via caspase-dependent nonapoptotic signaling. Cell Death Dis 2019;10:797.
28. Wu Y, Zhang J, Zhang H, Zhai Y. Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma. Oncol Lett 2016;12:1971-4.
29. Wang J, Ma L, Weng W, et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology 2013;58:1011-20.
30. Zhang T, Zhang J, You X, et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 2012;56:2051-9.
31. Oda C, Kamimura K, Shibata O, et al. HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma. Biochem Biophys Rep 2022;32:101352.
32. Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett 2016;12:3045-50.
33. Younis NS, Ghanim AMH, Saber S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci Rep 2019;9:19095.
34. Marra M, Sordelli IM, Lombardi A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011;9:171.
35. Méndez-Sánchez N, Vásquez-Fernández F, Zamora-Valdés D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol 2008;7:46-51.
36. Tu W, Gong J, Tian D, Wang Z. Hepatitis B virus X protein induces SATB1 expression through activation of ERK and p38MAPK pathways to suppress anoikis. Dig Dis Sci 2019;64:3203-14.
37. Shan C, Xu F, Zhang S, et al. Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res 2010;20:563-75.
38. Liao B, Zhou H, Liang H, Li C. Regulation of ERK and AKT pathways by hepatitis B virus X protein via the Notch1 pathway in hepatocellular carcinoma. Int J Oncol 2017;51:1449-59.
39. Orzechowska M, Anusewicz D, Bednarek AK. Functional gene expression differentiation of the notch signaling pathway in female reproductive tract tissues-a comprehensive review with analysis. Front Cell Dev Biol 2020;8:592616.
40. Amata I, Maffei M, Pons M. Phosphorylation of unique domains of Src family kinases. Front Genet 2014;5:181.
41. Belli S, Esposito D, Servetto A, Pesapane A, Formisano L, Bianco R. c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve? Cancers 2020;12:1489.
42. Yang J, Zhang X, Liu L, Yang X, Qian Q, Du B. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway. Life Sci 2021;264:118711.
43. Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2020;21:341-52.
44. Yang SZ, Zhang LD, Zhang Y, et al. HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun 2009;382:555-60.
45. Long HZ, Cheng Y, Zhou ZW, Luo HY, Wen DD, Gao LC. PI3K/AKT signal pathway: a target of natural products in the prevention and treatment of alzheimer’s disease and parkinson’s disease. Front Pharmacol 2021;12:648636.
46. Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 2015;9:317-24.
47. Wang Z, Cui X, Hao G, He J. Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma. Open Life Sci 2021;16:1037-44.
48. Wang HY, Yang SL, Liang HF, Li CH. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int J Mol Sci 2014;15:3507-18.
49. Xiang K, Wang B. Role of the PI3K-AKT-mTOR pathway in hepatitis B virus infection and replication. Mol Med Rep 2018;17:4713-9.
50. Zhu M, Guo J, Li W, et al. HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells. BMC Cancer 2015;15:362.
51. Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol 2015;89:999-1012.
52. Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F, Jalalian FA. Complexity on modulation of NF-κB pathways by hepatitis B and C: a double-edged sword in hepatocarcinogenesis. J Cell Physiol 2019;234:14734-42.
53. You H, Qin S, Zhang F, et al. Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection. Front Immunol 2022;13:829923.
54. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80:1197-213.
55. Quétier I, Brezillon N, Duriez M, et al. Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. J Hepatol 2013;59:285-91.
56. Wang Y, Cui L, Yang G, et al. Hepatitis B e antigen inhibits NF-κB activity by interrupting K63-linked ubiquitination of NEMO. J Virol 2019;93:e00667-18.
57. Cho IR, Oh M, Koh SS, et al. Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med 2012;29:581-6.
58. Yang Y, Zheng B, Han Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther 2016;17:449-56.
59. Azbazdar Y, Karabicici M, Erdal E, Ozhan G. Regulation of wnt signaling pathways at the plasma membrane and their misregulation in cancer. Front Cell Dev Biol 2021;9:631623.
60. Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol 2019;25:42-58.
61. Nuñez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV. Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. PLoS One 2011;6:e18562.
62. Zheng BY, Gao WY, Huang XY, et al. HBx promotes the proliferative ability of HL-7702 cells via the COX-2/Wnt/β-catenin pathway. Mol Med Rep 2018;17:8432-8.
63. Srisuttee R, Koh SS, Kim SJ, et al. Hepatitis B virus X (HBX) protein upregulates β-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase. Oncol Rep 2012;28:276-82.
64. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004;39:1683-93.
65. Prud’homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87:1077-91.
66. Chen J, Gingold JA, Su X. Immunomodulatory TGF-β signaling in hepatocellular carcinoma. Trends Mol Med 2019;25:1010-23.
67. Liu Y, Xu Y, Ma H, et al. Hepatitis B virus X protein amplifies TGF-β promotion on HCC motility through down-regulating PPM1a. Oncotarget 2016;7:33125-35.
68. Dong KS, Chen Y, Yang G, et al. TGF-β1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p. Oncogene 2020;39:1807-20.
69. Lim HY, Han J, Yoon H, Jang KL. Tumor suppressor p53 inhibits hepatitis B virus replication by downregulating HBx via E6AP-mediated proteasomal degradation in human hepatocellular carcinoma cell lines. Viruses 2022;14:2313.
70. Yang Y, Qu Y, Li Z, Tan Z, Lei Y, Bai S. Identification of novel characteristics in TP53-mutant hepatocellular carcinoma using bioinformatics. Front Genet 2022;13:874805.
71. Chan C, Thurnherr T, Wang J, et al. Global re-wiring of p53 transcription regulation by the hepatitis B virus X protein. Mol Oncol 2016;10:1183-95.
72. Lacal I, Ventura R. Epigenetic inheritance: concepts, mechanisms and perspectives. Front Mol Neurosci 2018;11:292.
73. Tian Y, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol 2013;33:2810-6.
74. Lee SM, Lee YG, Bae JB, et al. HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators. Proc Natl Acad Sci USA 2014;111:9555-60.
75. Jiang Y, Han Q, Zhao H, Zhang J. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma 2021;8:435-50.
76. Mahmoudvand S, Shokri S. Effect of lactate on epigenetic regulation in the development of hepatitis B virus-related hepatocellular carcinoma. J Clin Transl Hepatol 2022;10:786-7.
77. Kesheh MM, Mahmoudvand S, Shokri S. Long noncoding RNAs in respiratory viruses: a review. Rev Med Virol 2022;32:e2275.
78. Lin X, Xiang X, Feng B, et al. Targeting long non-coding RNAs in hepatocellular carcinoma: progress and prospects. Front Oncol 2021;11:670838.
79. Hu JJ, Song W, Zhang SD, et al. HBx-upregulated lncRNA UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and repressing p27Kip1/CDK2 signaling. Sci Rep 2016;6:23521.
80. Salerno D, Chiodo L, Alfano V, et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Gut 2020;69:2016-24.
81. Samudh N, Shrilall C, Arbuthnot P, Bloom K, Ely A. Diversity of dysregulated long non-coding RNAs in HBV-related hepatocellular carcinoma. Front Immunol 2022;13:834650.
82. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther 2016;1:15004.
83. Sartorius K, Swadling L, An P, et al. The multiple roles of hepatitis B virus X protein (HBx) dysregulated MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways. Viruses 2020;12:746.
84. Tian Y, Xiao X, Gong X, et al. HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN. Sci Rep 2017;7:40089.
85. Zhang Q, Song G, Yao L, et al. miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3. J Exp Clin Cancer Res 2018;37:14.
86. Yang S, Yang L, Li X, et al. New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. Am J Cancer Res 2019;9:1329-53.
87. Liu L, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget 2017;8:57707-22.
88. Cui J, Shen HM, Lim LHK. The role of autophagy in liver cancer: crosstalk in signaling pathways and potential therapeutic targets. Pharmaceuticals 2020;13:432.
89. Wang P, Guo QS, Wang ZW, Qian HX. HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway. Mol Cell Biochem 2013;372:161-8.
90. Son J, Kim MJ, Lee JS, Kim JY, Chun E, Lee KY. Hepatitis B virus X protein promotes liver cancer progression through autophagy induction in response to TLR4 stimulation. Immune Netw 2021;21:e37.
91. Luo MX, Wong SH, Chan MT, et al. Autophagy mediates HBx-Induced nuclear factor-κB activation and release of IL-6, IL-8, and CXCL2 in hepatocytes. J Cell Physiol 2015;230:2382-9.
92. Jeon JS, Kwon S, Ban K, et al. Regulation of the intracellular ROS level is critical for the antiproliferative effect of quercetin in the hepatocellular carcinoma cell line HepG2. Nutr Cancer 2019;71:861-9.
93. Nour H, Maroua C, Samir D. A study of the relationship between oxidative stress and risk of developing hepatocellular carcinoma in people with hepatitis B infection; A systematic review study. Asian Pac J Cancer Biol 2021;6:316-20.
94. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006;5:14.
95. Ha HL, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. World J Gastroenterol 2010;16:4932-7.
96. Lim W, Kwon SH, Cho H, et al. HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J Mol Med 2010;88:359-69.
97. Suhail M, Sohrab SS, Kamal MA, Azhar EI. Role of hepatitis C virus in hepatocellular carcinoma and neurological disorders: an overview. Front Oncol 2022;12:913231.
98. Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virol J 2012;9:57.
99. Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Ind J Med Res 2010;131:17-34.
100. Vranjkovic A, Deonarine F, Kaka S, Angel JB, Cooper CL, Crawley AM. Direct-acting antiviral treatment of HCV infection does not resolve the dysfunction of circulating CD8+ T-cells in advanced liver disease. Front Immunol 2019;10:1926.
101. Heredia-Torres TG, Rincón-Sánchez AR, Lozano-Sepúlveda SA, et al. Unraveling the molecular mechanisms involved in HCV-induced carcinogenesis. Viruses 2022;14:2762.
102. Ivanov AV, Bartosch B, Smirnova OA, Isaguliants MG, Kochetkov SN. HCV and oxidative stress in the liver. Viruses 2013;5:439-69.
104. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-56.
105. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22 Suppl 1:S108-11.
106. Ivanov AV, Smirnova OA, Ivanova ON, Masalova OV, Kochetkov SN, Isaguliants MG. Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells. PLoS One 2011;6:e24957.
107. Ming-Ju H, Yih-Shou H, Tzy-Yen C, Hui-Ling C. Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line. J Cell Biochem 2011;112:233-43.
108. Li S, Ye L, Yu X, et al. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation. Virology 2009;391:257-64.
109. Yen HH, Shih KL, Lin TT, Su WW, Soon MS, Liu CS. Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C. World J Gastroenterol 2012;18:5084-9.
110. Piccoli C, Quarato G, Ripoli M, et al. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim Biophys Acta 2009;1787:539-46.
111. Piccoli C, Scrima R, D’Aprile A, et al. Mitochondrial dysfunction in hepatitis C virus infection. Biochim Biophys Acta 2006;1757:1429-37.
112. Qadri I, Iwahashi M, Capasso JM, et al. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J 2004;378:919-28.
113. Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol 2022;86:622-32.
114. Braghini MR, Lo Re O, Romito I, et al. Epigenetic remodelling in human hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:107.
115. Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: from sorafenib to natural products. Eur J Med Chem 2021;224:113690.
116. Shigekawa Y, Hayami S, Ueno M, et al. Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget 2018;9:34320-35.
117. Zhou P, Xia J, Zhou YJ, et al. Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients. World J Gastroenterol 2015;21:6665-74.
118. Glozak MA, Seto E. Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem 2009;284:11446-53.
119. Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-coding RNAs and hepatitis C virus-induced hepatocellular carcinoma. Viruses 2018;10:591.
120. Diaz G, Melis M, Tice A, et al. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer 2013;133:816-24.
121. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537-45.
122. Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-Related hepatocellular carcinoma. Int J Mol Sci 2018;19:1007.
123. Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007;13:5180-7.
124. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004;24:399-413.
126. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-30.
127. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009;44 Suppl 19:82-8.
128. Saad Y, Shaker O, Nassar Y, Ahmad L, Said M, Esmat G. A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection. Gut Liver 2014;8:655-61.
129. Hino K, Hara Y, Nishina S. Mitochondrial reactive oxygen species as a mystery voice in hepatitis C. Hepatol Res 2014;44:123-32.
130. Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012;86:6315-22.
131. Deng L, Shoji I, Ogawa W, et al. Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol 2011;85:8556-68.
132. Loftus LV, Amend SR, Pienta KJ. Interplay between cell death and cell proliferation reveals new strategies for cancer therapy. Int J Mol Sci 2022;23:4723.
133. Tavakolian S, Goudarzi H, Faghihloo E. Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers. Infect Agent Cancer 2020;15:27.
134. Gutierrez-Chamorro L, Felip E, Ezeonwumelu IJ, Margelí M, Ballana E. Cyclin-dependent kinases as emerging targets for developing novel antiviral therapeutics. Trends Microbiol 2021;29:836-48.
135. Otsuka M, Kato N, Lan K, et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 2000;275:34122-30.
136. Wang F, Yoshida I, Takamatsu M, et al. Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochem Biophys Res Commun 2000;273:479-84.
137. Kwun HJ, Jang KL. Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J Viral Hepat 2003;10:249-55.
138. Munakata T, Nakamura M, Liang Y, Li K, Lemon SM. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 2005;102:18159-64.
139. Masalova OV, Lesnova EI, Solyev PN, et al. Modulation of cell death pathways by hepatitis C virus proteins in Huh7.5 hepatoma cells. Int J Mol Sci 2017;18:2346.
140. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 2022;12:985363.
141. Otsuka M, Kato N, Taniguchi H, et al. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology 2002;296:84-93.
142. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect 2016;22:853-61.
143. Cheng D, Zhang L, Yang G, et al. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int 2015;35:1682-91.
144. Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS 2017;12:302-14.
145. Hong YS, Chang Y, Ryu S, et al. Hepatitis B and C virus infection and diabetes mellitus: a cohort study. Sci Rep 2017;7:4606.
147. Vallianou NG, Evangelopoulos A, Kazazis C. Metformin and cancer. Rev Diabet Stud 2013;10:228-35.
148. Schutte SC, Taylor RN. A tissue-engineered human endometrial stroma that responds to cues for secretory differentiation, decidualization, and menstruation. Fertil Steril 2012;97:997-1003.
149. Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2014;45:322-32.
150. Zhang X, Liu P, Shang Y, et al. Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. J Cancer 2020;11:479-87.
151. Kamarudin MNA, Sarker MMR, Zhou JR, Parhar I. Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects. J Exp Clin Cancer Res 2019;38:491.
152. Chen J, Chen X. MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol Res 2018;26:913-22.
153. Casadei Gardini A, Faloppi L, De Matteis S, et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale. Eur J Cancer 2017;86:106-14.
154. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J, Pan Y. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 2012;42:922-33.
155. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66.
156. Rich NE. Changing epidemiology of hepatocellular carcinoma within the United States and worldwide. Surg Oncol Clin N Am 2024;33:1-12.
157. Garuti F, Neri A, Avanzato F, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2021;41:585-97.
158. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253-70.
159. Krishan S, Richardson DR, Sahni S. Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol 2015;87:363-77.
160. Oo YH, Sakaguchi S. Regulatory T-cell directed therapies in liver diseases. J Hepatol 2013;59:1127-34.
161. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
162. Zheng MH, Gu DN, Braddock M, et al. CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases. Expert Opin Ther Targets 2008;12:313-26.
163. Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: a review. World J Gastroenterol 2019;25:3527-37.
164. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003;38:1437-48.
165. Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021;27:2994-3009.
166. Takahashi A, Kimura F, Yamanaka A, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 2014;14:53.
167. Gao C, Fang L, Zhang H, Zhang WS, Li XO, Du SY. Metformin induces autophagy via the AMPK-mTOR signaling pathway in human hepatocellular carcinoma cells. Cancer Manag Res 2020;12:5803-11.
168. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98.
169. Choi J, Roberts LR. Statins and metformin for chemoprevention of hepatocellular carcinoma. Clin Liver Dis 2016;8:48-52.
170. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601-8.
171. Del Campo JA, García-Valdecasas M, Gil-Gómez A, et al. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS One 2018;13:e0191805.
172. Xie W, Wang L, Sheng H, et al. Metformin induces growth inhibition and cell cycle arrest by upregulating MicroRNA34a in renal cancer cells. Med Sci Monit 2017;23:29-37.
173. Li JH, Wang Y, Xie XY, et al. Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. Am J Cancer Res 2016;6:2109.
174. Jung WJ, Jang S, Choi WJ, et al. Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. Sci Rep 2022;12:14482.
175. Zhou X, Chen J, Yi G, et al. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 2016;7:873-84.
176. Chen ML, Wu CX, Zhang JB, et al. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. Front Endocrinol 2022;13:996228.
177. Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology 2014;87 Suppl 1:22-31.
178. Abdelmonsif DA, Sultan AS, El-Hadidy WF, Abdallah DM. Targeting AMPK, mTOR and β-catenin by combined metformin and aspirin therapy in HCC: an appraisal in egyptian HCC patients. Mol Diagn Ther 2018;22:115-27.
179. Ielasi L, Tovoli F, Tonnini M, et al. Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders. Cancers 2021;13:6376.
180. Pasche B, Wang M, Pennison M, Jimenez H. Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol 2014;41:397-401.
181. Kasmari AJ, Welch A, Liu G, Leslie D, McGarrity T, Riley T. Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome. Am J Med 2017;130:746.e1-7.
182. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46-52.
183. Chen CI, Kuan CF, Fang YA, et al. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine 2015;94:e462.
184. Vilar-Gomez E, Vuppalanchi R, Desai AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2019;50:317-28.
185. Tsai PC, Kuo HT, Hung CH, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol 2023;78:281-92.
186. Shen C, Peng C, Shen B, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. Oncotarget 2016;7:62647-56.
187. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010;6:457-70.
188. Jiang X, Tan HY, Teng S, Chan YT, Wang D, Wang N. The role of AMP-activated protein kinase as a potential target of treatment of hepatocellular carcinoma. Cancers 2019;11:647.
189. Nakashima K, Takeuchi K, Chihara K, Hotta H, Sada K. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. Microbiol Immunol 2011;55:774-82.
190. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
191. Zheng L, Yang W, Wu F, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res 2013;19:5372-80.
192. Hu JW, Chen B, Zhang J, et al. Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of hepatocellular carcinoma. J Cancer 2020;11:6437-44.
193. Ling S, Song L, Fan N, et al. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. Int J Oncol 2017;50:297-309.
194. Sun R, Zhai R, Ma C, Miao W. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway. Cancer Med 2020;9:1141-51.
196. Sultuybek G, Soydas T, Yenmis G. NF-κB as the mediator of metformin’s effect on ageing and ageing-related diseases. Clin Exp Pharmacol Physiol 2019;46:413-22.
197. Luedde T, Schwabe RF. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-18.
198. He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68.
199. Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol 2021;11:760971.
202. Wipperman MF, Montrose DC, Gotto AM Jr, Hajjar DP. Mammalian target of rapamycin: a metabolic rheostat for regulating adipose tissue function and cardiovascular health. Am J Pathol 2019;189:492-501.
203. Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020;21:1266.
204. Wang Z, Jin W, Jin H, Wang X. mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int 2014;2014:735672.
205. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007;13:4865-72.
207. Yi Y, Zhang W, Yi J, Xiao ZX. Role of p53 family proteins in metformin anti-cancer activities. J Cancer 2019;10:2434-42.
208. Lu G, Wu Z, Shang J, Xie Z, Chen C, Zhang C. The effects of metformin on autophagy. Biomed Pharmacother 2021;137:111286.
209. Lin D, Reddy V, Osman H, et al. Additional inhibition of Wnt/β-catenin signaling by metformin in DAA Treatments as a novel therapeutic strategy for HCV-infected patients. Cells 2021;10:790.
210. Cai W, Ma Y, Song L, et al. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K/akt and RAS/raf/ERK signaling pathways. BMC Cancer 2023;23:87.
211. Vacante F, Senesi P, Montesano A, Paini S, Luzi L, Terruzzi I. Metformin counteracts HCC progression and metastasis enhancing KLF6/p21 expression and downregulating the IGF axis. Int J Endocrinol 2019;2019:7570146.
212. Geh D, Anstee QM, Reeves HL. NAFLD-associated HCC: progress and opportunities. J Hepatocell Carcinoma 2021;8:223-39.
213. Adinolfi LE, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016;17:803.
214. Wang B, Li W, Fang H, Zhou H. Hepatitis B virus infection is not associated with fatty liver disease: evidence from a cohort study and functional analysis. Mol Med Rep 2019;19:320-6.
215. Zhang Y, Wang H, Xiao H. Metformin actions on the liver: protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC. Int J Mol Sci 2021;22:5016.
Cite This Article
Export citation file: BibTeX | RIS
OAE Style
Shojaeian A, Nakhaie M, Amjad ZS, Boroujeni AK, Shokri S, Mahmoudvand S. Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections. J Cancer Metastasis Treat 2024;10:5. http://dx.doi.org/10.20517/2394-4722.2023.147
AMA Style
Shojaeian A, Nakhaie M, Amjad ZS, Boroujeni AK, Shokri S, Mahmoudvand S. Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections. Journal of Cancer Metastasis and Treatment. 2024; 10: 5. http://dx.doi.org/10.20517/2394-4722.2023.147
Chicago/Turabian Style
Shojaeian, Ali, Mohsen Nakhaie, Zahra Sobhi Amjad, Armin Khaghani Boroujeni, Somayeh Shokri, Shahab Mahmoudvand. 2024. "Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections" Journal of Cancer Metastasis and Treatment. 10: 5. http://dx.doi.org/10.20517/2394-4722.2023.147
ACS Style
Shojaeian, A.; Nakhaie M.; Amjad ZS.; Boroujeni AK.; Shokri S.; Mahmoudvand S. Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections. J. Cancer. Metastasis. Treat. 2024, 10, 5. http://dx.doi.org/10.20517/2394-4722.2023.147
About This Article
Copyright
Data & Comments
Data
0
Cite This Article 6 clicks
Like This Article 13
likes
Comments
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.